[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 443, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 61, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1115221, "exercisedValue": 2853049, "unexercisedValue": 32777390}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 665284, "exercisedValue": 1024663, "unexercisedValue": 1206837}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 60, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 811075, "exercisedValue": 1681564, "unexercisedValue": 10104314}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 62, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 812175, "exercisedValue": 0, "unexercisedValue": 7521715}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 52, "title": "Executive Vice President of Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 633737, "exercisedValue": 0, "unexercisedValue": 7283126}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 42, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 56.75, "open": 60.0, "dayLow": 57.77, "dayHigh": 60.53, "regularMarketPreviousClose": 56.75, "regularMarketOpen": 60.0, "regularMarketDayLow": 57.77, "regularMarketDayHigh": 60.53, "beta": 1.435, "forwardPE": -15.2750635, "volume": 2397781, "regularMarketVolume": 2397781, "averageVolume": 1087992, "averageVolume10days": 1819770, "averageDailyVolume10Day": 1819770, "bid": 59.36, "ask": 59.45, "bidSize": 600, "askSize": 600, "marketCap": 9925457920, "fiftyTwoWeekLow": 18.79, "fiftyTwoWeekHigh": 60.53, "priceToSalesTrailing12Months": 13376.628, "fiftyDayAverage": 46.5444, "twoHundredDayAverage": 39.22755, "currency": "USD", "enterpriseValue": 8422150144, "floatShares": 153647431, "sharesOutstanding": 167039008, "sharesShort": 16662899, "sharesShortPriorMonth": 17165007, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0998, "heldPercentInsiders": 0.02141, "heldPercentInstitutions": 1.0426899, "shortRatio": 14.51, "shortPercentOfFloat": 0.106300004, "bookValue": 9.773, "priceToBook": 6.080016, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -519207008, "trailingEps": -3.72, "forwardEps": -3.89, "enterpriseToRevenue": 11350.606, "enterpriseToEbitda": -14.789, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RVMD", "underlyingSymbol": "RVMD", "shortName": "Revolution Medicines, Inc.", "longName": "Revolution Medicines, Inc.", "firstTradeDateEpochUtc": 1581604200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2cb08d82-911b-38e3-94c5-2f2b3c1d7099", "gmtOffSetMilliseconds": -18000000, "currentPrice": 59.42, "targetHighPrice": 82.0, "targetLowPrice": 55.0, "targetMeanPrice": 64.85, "targetMedianPrice": 62.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 1590715008, "totalCashPerShare": 9.523, "ebitda": -569468992, "totalDebt": 87411000, "quickRatio": 15.102, "currentRatio": 15.425, "totalRevenue": 742000, "debtToEquity": 5.4, "revenuePerShare": 0.005, "returnOnAssets": -0.24948, "returnOnEquity": -0.40727, "freeCashflow": -281241984, "operatingCashflow": -509787008, "operatingMargins": -775.24664, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]